From BigGo Finance · BigGo Finance · · 50s
Keymed Bio's Stapokibart Revenue Surges
Keymed Bio's Stapokibart posts 660 million yuan in first three quarters, shares jump 10.51%.
In brief
Keymed Bio's Stapokibart posts 660 million yuan in first three quarters, shares jump 10.51%. Keymed Bio's Stapokibart generated 660 million yuan in revenue for 2026 Q1-Q3, up 227% year-over-year, with shares rising 10.51%. Originally reported by BigGo Finance.
Keymed Bio Announces Revenue
Keymed Bio reported its core product Kangyueda generated 660 million yuan in revenue for the first three quarters of 2026, up 227% year-over-year.
Shares Surge 10.51%
The company's shares rose 10.51% to HK$84.15 (approximately $11) after the announcement.
New Atopic Dermatitis Approval
China's National Medical Products Administration approved stapokibart for moderate-to-severe atopic dermatitis in adolescents.
Clinical Results
Phase III data showed 73.9% EASI-75 response rate at week 18, significantly higher than placebo's 43.3%.
The main idea
Keymed Bio's Stapokibart generated 660 million yuan in revenue for 2026 Q1-Q3, up 227% year-over-year, with shares rising 10.51%.
